Method for the prevention of a patient's fibroproliferative vasc

Details Method for the prevention of a patient's fibroproliferative vasc Method for the prevention of a patient's fibroproliferative vasc

1998-03-27

2000-09-26

Jones, Dwayne C.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 12, 514 13, 514 14, 530311, A61K 3800

Patent

active

06124256&

ABSTRACT:
A method for the prevention of a patient's fibroproliferative vasculopathy following vascular injury or a vascular surgical operation. The method includes administering to the patient an agonist specific for at least one somatostatin (SST) receptor showing an increased expression in the patient's vascular wall subsequent to injury or operation, the administering being carried out for one to two weeks after the injury or surgical operation.

REFERENCES:
Wahlers et al., The Journal of Heart and Lung Transp., vol. 14, No. 1, Part 1, 143-150, 1995.
Hcaplus on 128: 136659, Zhao et al., Prustaglandins, 54(5), 781-793 (abstract), 1997.
Hcaplus on 125: 185985, Mutumura et al., Transplant Immunol., 4(2), 99-104, 1996.
WPIDS Doc. No. CPI: C98-013891, WO 9743278, 1997.
Hcaplus on 120:125371, Howell et al., Clin. Sci 85(2), 183-188, 1993.
Eriksen et al., "Randomized Double-blind Scandinavian trial . . . ," American Heart J. 130(1):1-8 (1995) (Abstract).
Emanuelsson et al., "Coronary Heart Disease/Myocardial . . . ," Circulation 91(6):1689-1696 (1995).
von Essen et al., "Effects of Octreotide Treatment . . . ," Circulation 96(5):1482-1487 (1997).
Foegh et al., "Early Inhibition of Myointimal Proliferation . . . ," J. Vasc. Surg., 19(6):1084-1091 (1994) (Abstract).
Foegh et al., "Angiopeptin: Experimental and Clinical Studies . . . ," Kidney Int.--Supp, 52:S18-22 (1995) (Abstract).
Galis et al., "Enhanced Expression of Vascular Matrix . . . ," Ann. NY Acad. Sci., 748:501-507 (1995) (Abstract).
Goldberg et al., "Vascular Smooth Muscle Cell Kinetics . . . ," Science 205 (4409):920-922 (1979) (Abstract).
Grant et al., "Localization of Insulin-like Growth Factor . . . ," Circulation 89 (4):1511-1517 (1994).
Yumi et al., "Direct Effects of Somatostatin Analog . . . ," Lab. Invest. 76 (3):329-338 (1997) (Abstract).
Hayry et al., "Somatostatin Analog Lanreotide Inhibits . . . ," FASEB J., 7:1055-1060 (1993).
Khare et al., "Differential Regulation of Somatostatin Receptor Types 1-5 in Rat Aorta After Angioplasty," 13 FASB J. 387-394 (Feb. 1999).
Weckbecker et al., "The Somatostatin Analog Octreotide as Potential Treatment for Re-Stenosis . . ," 29 Transplantation Proc. 2599-2600 (1997).
Chen et al., "Somatostatin Receptor Expression in Rat Iliac Arteries After Balloon Injury," 10 J. Investigative Surg. 17-23 (1997).
Patel, "Molecular Pharmacology of Somatostatin Receptor Subtypes," 20 J. Endocrinol. Invest. 348-367 (1997).

Affiliated with

Also associated with

Rating

Method for the prevention of a patient's fibroproliferative vasc does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for the prevention of a patient's fibroproliferative vasc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the prevention of a patient's fibroproliferative vasc will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2100162